Biogen Idec To Pursue Disability Label Claim For BG-12 Despite Missed Endpoint
This article was originally published in The Pink Sheet Daily
Executive Summary
Relapse reduction in multiple sclerosis was robust, though lower than in the first Phase III trial, but the drug missed the statistical mark on disability progression.